Literature DB >> 25784373

Establishment of a novel human papillomavirus-negative and radiosensitive head and neck squamous cell carcinoma cell line.

Kyung-Min Kim1, Eun-Ji Park2, Jiyoung Yeo3, Young-Hoon Joo4, Kwang-Jae Cho4, Min-Sik Kim4.   

Abstract

BACKGROUND: The purpose of this study was to develop a CMCSCC-1 cell line for head and neck cancer research into new therapies for head and neck squamous cell carcinoma (HNSCC).
METHODS: The CMCSCC-1 cell line was isolated from a primary oral tongue tumor specimen of a female patient. Tumor cells were evaluated for biomarkers expression by Western blots, reverse transcriptase-polymerase chain reaction (RT-PCR), fluorescence activated cell sorter, and immunostaining. Cell proliferation in response to radiation was measured by the WST-8 assay.
RESULTS: The characterization analyses revealed a typical epithelial morphology; a doubling time of approximately 24 hours, high tumorigenicity in immunodeficient mice, and upregulated biomarkers. CMCSCC-1 cells were negative for human papillomavirus (HPV) infection, but more sensitive to radiation compared with those FaDu cell lines.
CONCLUSION: CMCSCC-1, a novel oral tongue SCC cell line, was established. It will help in the elucidation of the molecular pathogenesis of HPV-negative radiosensitive tumors.
© 2015 Wiley Periodicals, Inc. Head Neck 38: E542-E551, 2015. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  head and neck neoplasms; human papillomavirus; radiotherapy; squamous cell carcinoma; tumor cell line

Mesh:

Substances:

Year:  2015        PMID: 25784373     DOI: 10.1002/hed.24037

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  1 in total

1.  Establishment and characterization of a squamous cell carcinoma cell line, designated hZK-1, derived from a metastatic lymph node tumor of the tongue.

Authors:  Tetsuya Hirabayashi; Haruka Takahashi; Miho Watanabe; Toshiaki Tachibana
Journal:  Hum Cell       Date:  2017-03-04       Impact factor: 4.174

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.